Table of contents
Solensia is a veterinary medicinal product, which contains the active substance frunevetmab. It is used in cats to relieve pain associated with osteoarthritis.
For more information, see the package leaflet.
Solensia : EPAR - Medicine overview (PDF/134.72 KB)
First published: 25/06/2021
|Agency product number||
|International non-proprietary name (INN) or common name||
Zoetis Belgium SA
|Date of issue of marketing authorisation valid throughout the European Union||
Rue Laid Burniat 1
17/02/2021 Solensia - EMEA/V/C/005179 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 18-19 January 202221/01/2022
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 8-10 December 202011/12/2020